title: The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
abstract: The PcrV cap structure of the type III secretory apparatus of Pseudomonas aeruginosa is a vaccine target. Human immunoglobulin G (IgG) molecules extracted from sera containing high or low anti-PcrV titers were tested for their effects against P. aeruginosa pneumonia in a mouse model. Among 198 volunteers, we selected the top 10 high anti-PcrV titer sera and the bottom 10 low anti-PcrV titer sera and extracted the IgG fraction from each serum sample. First, we examined the effects of the IgG against virulent P. aeruginosa. A lethal dose of P. aeruginosa premixed with saline, low titer human IgG, high titer human IgG, or rabbit-derived polyclonal anti-PcrV IgG was intratracheally administered into the lungs of mice, and their survival and lung inflammation were evaluated for 24 h. The high anti-PcrV titer human IgG had a prophylactic effect. Next, the prophylactic effects of intravenous administration of extracted and pooled high or low anti-PcrV titer human IgG were examined. Here, prophylactic intravenous administration of pooled high anti-PcrV titer human IgG, which showed binding capacity to P. aeruginosa PcrV, was more effective than the administration of its low titer pooled equivalent, and the measured physiological and inflammatory parameters correlated with the anti-PcrV titer levels. This result indirectly implies that high anti-PcrV titers in blood can help to protect against virulent P. aeruginosa infections. In addition, the IgG fractions from such high titer sera have potential to be a source of specific intravenous immunoglobulin products for passive vaccination against virulent P. aeruginosa infections.
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Mao
authors.initials: M
authors.lastname: Kinoshita
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Hideya
authors.initials: H
authors.lastname: Kato
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yasumoto
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Shimizu
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Saeko
authors.initials: S
authors.lastname: Hamaoka
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Naito
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Akiyama
authors.affiliation: b Department of Anesthesiology , School of Medicine, Kyorin University , Mitaka , Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Moriyama
authors.affiliation: a Department of Anesthesiology , Kyoto Prefectural University of Medicine , Kyoto , Japan.
authors.forename: Teiji
authors.initials: T
authors.lastname: Sawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000276:immunology; D018890:Chemoprevention / Q000379:methods; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000276:immunology; D008297:Male; D051379:Mice; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000517:prevention & control*; D052899:Pore Forming Cytotoxic Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D011817:Rabbits; D016019:Survival Analysis; D014838:Volunteers
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D007074:Immunoglobulin G; D052899:Pore Forming Cytotoxic Proteins; C118546:antigen V, Pseudomonas
keywords: PcrV; Pseudomonas aeruginosa; anti-PcrV titer; bacterial pneumonia; intravenous immunoglobulin; type III secretion system